T D Sandahl1, R McGrail2, H J Møller2, E Reverter3, S Møller4, F Turon3, V Hernández-Gea3, F Bendtsen5, H Vilstrup1, J C Garcia-Pagan3, H Grønbaek1. 1. Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. 3. Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Barcelona, Spain. 4. Department of Clinical Physiology and Nuclear Medicine, 239 Center for Functional and Diagnostic Imaging and Research, Faculty of Health Sciences Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark. 5. Gastroenterology Unit, Medical Section, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
Abstract
BACKGROUND: Noninvasive identification of significant portal hypertension in patients with cirrhosis is needed in hepatology practice. AIM: To investigate whether the combination of sCD163 as a hepatic inflammation marker and the fibrosis markers of the Enhanced Liver Fibrosis score (ELF) can predict portal hypertension in patients with cirrhosis. METHODS: We measured sCD163 and the ELF components (hyaluronic acid, tissue inhibitor of metalloproteinase-1 and procollagen-III aminopeptide) in two separate cohorts of cirrhosis patients that underwent hepatic vein catheterisation. To test the predictive accuracy we developed a CD163-fibrosis portal hypertension score in an estimation cohort (n = 80) and validated the score in an independent cohort (n = 80). A HVPG ≥10 mmHg was considered clinically significant. RESULTS: Both sCD163 and the ELF components increased in a stepwise manner with the patients' Child-Pugh score (P < 0.001, all), and also with increasing HVPG (P < 0.001). receiver operator characteristics (ROC) analyses showed that each one of the individual components predicted a HVPG >10 mmHg with AUROC's of approximately 0.80. The combined score optimised by logistic regression analyses improved the AUROC to 0.91 in the estimation cohort and 0.90 in the validation cohort. Furthermore, a high value of the combined score was associated with a high short-term mortality. CONCLUSIONS: The combination of the macrophage activation marker sCD163 and the fibrosis markers predicted significant portal hypertension in patients with cirrhosis. This score may prove useful for screening purposes and highlights the importance of both the inflammatory and the fibrotic components of cirrhotic portal hypertension.
BACKGROUND: Noninvasive identification of significant portal hypertension in patients with cirrhosis is needed in hepatology practice. AIM: To investigate whether the combination of sCD163 as a hepatic inflammation marker and the fibrosis markers of the Enhanced Liver Fibrosis score (ELF) can predict portal hypertension in patients with cirrhosis. METHODS: We measured sCD163 and the ELF components (hyaluronic acid, tissue inhibitor of metalloproteinase-1 and procollagen-III aminopeptide) in two separate cohorts of cirrhosispatients that underwent hepatic vein catheterisation. To test the predictive accuracy we developed a CD163-fibrosis portal hypertension score in an estimation cohort (n = 80) and validated the score in an independent cohort (n = 80). A HVPG ≥10 mmHg was considered clinically significant. RESULTS: Both sCD163 and the ELF components increased in a stepwise manner with the patients' Child-Pugh score (P < 0.001, all), and also with increasing HVPG (P < 0.001). receiver operator characteristics (ROC) analyses showed that each one of the individual components predicted a HVPG >10 mmHg with AUROC's of approximately 0.80. The combined score optimised by logistic regression analyses improved the AUROC to 0.91 in the estimation cohort and 0.90 in the validation cohort. Furthermore, a high value of the combined score was associated with a high short-term mortality. CONCLUSIONS: The combination of the macrophage activation marker sCD163 and the fibrosis markers predicted significant portal hypertension in patients with cirrhosis. This score may prove useful for screening purposes and highlights the importance of both the inflammatory and the fibrotic components of cirrhotic portal hypertension.
Authors: Natasha McDonald; David M L Lilburn; Neil J Lachlan; Gillian Macnaught; Dilip Patel; Arjun N A Jayaswal; Peter C Hayes; Scott I Semple; Jonathan A Fallowfield Journal: Biomed Res Int Date: 2017-06-15 Impact factor: 3.411
Authors: Benedikt Simbrunner; Rodrig Marculescu; Bernhard Scheiner; Philipp Schwabl; Theresa Bucsics; Alexander Stadlmann; David J M Bauer; Rafael Paternostro; Ernst Eigenbauer; Matthias Pinter; Albert Friedrich Stättermayer; Michael Trauner; Mattias Mandorfer; Thomas Reiberger Journal: Liver Int Date: 2020-05-18 Impact factor: 5.828
Authors: Jean-Baptiste Gorin; David F G Malone; Benedikt Strunz; Tony Carlsson; Soo Aleman; Niklas K Björkström; Karolin Falconer; Johan K Sandberg Journal: Sci Rep Date: 2020-02-07 Impact factor: 4.379
Authors: Rasmus Hvidbjerg Gantzel; Mikkel Breinholt Kjær; Tea Lund Laursen; Konstantin Kazankov; Jacob George; Holger Jon Møller; Henning Grønbæk Journal: Front Med (Lausanne) Date: 2021-01-08
Authors: Lars Bossen; Mette Vesterhus; Johannes R Hov; Martti Färkkilä; William M Rosenberg; Holger J Møller; Kirsten M Boberg; Tom H Karlsen; Henning Grønbæk Journal: Clin Transl Gastroenterol Date: 2021-03-01 Impact factor: 4.396
Authors: Lukas Sturm; Dominik Bettinger; Lisa Roth; Katharina Zoldan; Laura Stolz; Chiara Gahm; Jan Patrick Huber; Marlene Reincke; Rafael Kaeser; Tobias Boettler; Wolfgang Kreisel; Robert Thimme; Michael Schultheiss Journal: Front Med (Lausanne) Date: 2022-01-04